Recent studies suggest that SGLT-2 inhibitors may have neuroprotective effects, including the reduction of amyloid beta accumulation in the brain, which is a hallmark of Alzheimer’s disease. The gene discussed is SLC5A2; the disease is early-onset autosomal dominant Alzheimer disease.